Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Keefe

Showing results (181-190 of 255) with videos related to

Pageof 26
Sort By:
Schizophrenia Research. Cognition|May 19, 2025
Assessment of the German Version of Brief Assessment of Cognition in Schizophrenia (BACS)Matin Mortazavi, Jakob Amon, Iris Jäger, et al.
Schizophrenia Research|August 30, 2005
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndromeJonathan M Meyer, Henry A Nasrallah, Joseph P McEvoy, et al.
Journal of Psychiatric Research|December 11, 2020
Can IQ moderate the response to cognitive remediation in people with schizophrenia?Benedetta Seccomandi, Deborah Agbedjro, Morris Bell, et al.
Schizophrenia Research|November 18, 2008
Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of functionLeah Kleinman, Jeffrey Lieberman, Sanjay Dube, et al.
Schizophrenia Bulletin|May 13, 2005
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophreniaRobert W Buchanan, Miriam Davis, Donald Goff, et al.
The American Journal of Psychiatry|June 18, 2013
Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) studyS Kristian Hill, James L Reilly, Richard S E Keefe, et al.
Schizophrenia Research. Cognition|February 16, 2026
Keep your participants close, but your informants closer? The added value of high and low contact informants to supplement self-report for the cognitive impairment of schizophreniaJayda L Melnitsky, Joanne Yoon, Megan R Mayer, et al.
The Lancet. Psychiatry|February 21, 2021
Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 studyW Wolfgang Fleischhacker, Jana Podhorna, Martina Gröschl, et al.
Schizophrenia Research|May 13, 2011
Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE studyT Scott Stroup, Paul S Appelbaum, Hongbin Gu, et al.
Dementia & Neuropsychologia|December 8, 2017
Sensitivity and applicability of the Brazilian version of the Brief Assessment of Cognition in Schizophrenia (BACS)João Vinícius Salgado, Carolina F Richards Carvalhaes, Annelise de Matos Pires, et al.
Pageof 26

Showing results (181-190 of 255) with videos related to

Sort By:
Pageof 26
Schizophrenia Research. Cognition|May 19, 2025
Assessment of the German Version of Brief Assessment of Cognition in Schizophrenia (BACS)Matin Mortazavi, Jakob Amon, Iris Jäger, et al.
Schizophrenia Research|August 30, 2005
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndromeJonathan M Meyer, Henry A Nasrallah, Joseph P McEvoy, et al.
Journal of Psychiatric Research|December 11, 2020
Can IQ moderate the response to cognitive remediation in people with schizophrenia?Benedetta Seccomandi, Deborah Agbedjro, Morris Bell, et al.
Schizophrenia Research|November 18, 2008
Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of functionLeah Kleinman, Jeffrey Lieberman, Sanjay Dube, et al.
Schizophrenia Bulletin|May 13, 2005
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophreniaRobert W Buchanan, Miriam Davis, Donald Goff, et al.
The American Journal of Psychiatry|June 18, 2013
Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) studyS Kristian Hill, James L Reilly, Richard S E Keefe, et al.
Schizophrenia Research. Cognition|February 16, 2026
Keep your participants close, but your informants closer? The added value of high and low contact informants to supplement self-report for the cognitive impairment of schizophreniaJayda L Melnitsky, Joanne Yoon, Megan R Mayer, et al.
The Lancet. Psychiatry|February 21, 2021
Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 studyW Wolfgang Fleischhacker, Jana Podhorna, Martina Gröschl, et al.
Schizophrenia Research|May 13, 2011
Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE studyT Scott Stroup, Paul S Appelbaum, Hongbin Gu, et al.
Dementia & Neuropsychologia|December 8, 2017
Sensitivity and applicability of the Brazilian version of the Brief Assessment of Cognition in Schizophrenia (BACS)João Vinícius Salgado, Carolina F Richards Carvalhaes, Annelise de Matos Pires, et al.
Pageof 26